Webinar: Regulatory Strategy in the EAEU and Rest of CIS Countries
Regulatory strategy in EAEU and CIS regions differ from other regions as market access to these countries can be a real challenge due to various local regulations. However, it is only a matter of experience and adequate know-how.
This webinar focuses on choosing your regulatory strategy for Eurasian Economic Union and Commonwealth of Independent States, best practices and practical tips for market access and current regulatory status and GMP requirements.
You will learn about:
1. Commonwealth of Independent States
- Differences and overlaps with EAEU
2. Regulatory strategy in the EAEU
- Current status and main challenges
- Practical tips
3. Regulatory strategy in the CIS region
- What is the current status?
- Best practices and key tips for main challenges
- GMP requirements in EAEU and CIS
Who should attend?
- Global and regional RA Managers
- Regulatory Strategy Managers
- RA Partnerships Operations Manager
- QA Managers supporting RA
- RA Healthcare Compliance Managers
Duration: 25 min.
Speaker: Regulatory Affairs Project Manager, Nargiz Asgarova, BSc, MBA, who will share her expertise on regulatory strategy in EAEU and CIS regions.
Nargiz Asgarova, BSc, MBA
Regulatory Affairs Project Manager
Entering EAEU or CIS markets?
Make use of our experts’ know-how to access new markets. Explore your options in an informal chat with one of our experts.
Other content that might interest you:
Practical tips on Affiliate Based Outsourcing including for Regulatory Affairsoptimization of local RA setup, management and relevant costs.
Company registration is part of the common regulatory requirements in several Middle Eastern and North African (MENA) countries. Nevertheless, it can be easily overlooked in preparation for drug filing and the overall regulatory picture. MENA countries are accepting...
Regulatory affairs for biosimilars in Middle East North Africa (MENA) region are evolving as existing guidelines and regulatory frameworks are being updated. Since European Medicines Agency (EMA) introduced a legal pathway for biosimilars approval in 2004, several...